SCHEMBL4990889

SCHEMBL4990889

Fc1ccc(-c2cncc(-c3ccco3)n2)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R1 P27986 5/20 0.51
PIK3CA P42336 5/20 0.51
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
PTGS1 P23219 1/20 0.40
HSD17B10 Q99714 6/20 0.39
MAPT P10636 5/20 0.39
ALDH1A1 P00352 4/20 0.39
TSHR P16473 3/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 3/20 0.39
USP2 O75604 3/20 0.39
GAA P10253 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
PSMD14 O00487 1/20 0.39
GLA P06280 1/20 0.39
KMO O15229 1/20 0.39
ALOX15 P16050 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3163523 0.79 ALDH1A1 (0.54) PIK3R1PIK3CAMEN1KMT2AHSD17B10
SCHEMBL28202407 0.78 PIK3R1 (0.56) PIK3R1PIK3CAMEN1KMT2APTGS1
SCHEMBL5000806 0.77 PIK3R1 (0.38) PIK3R1PIK3CAMEN1KMT2AHSD17B10
SCHEMBL5000809 0.76 FYN (0.52) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL13930938 0.72 RAB9A (0.58) PIK3R1PIK3CAMEN1KMT2AHSD17B10
SCHEMBL3251579 0.71 PIK3R1 (0.48) PIK3R1PIK3CAMEN1KMT2AHSD17B10
SCHEMBL13261826 0.70 KMO (0.51) MEN1KMT2AKMOL3MBTL1NPC1
SCHEMBL3263388 0.69 PIK3R1 (0.49) PIK3R1PIK3CAMEN1KMT2AHSD17B10
SCHEMBL3533444 0.68 PDE10A (0.46) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL3063935 0.68 MAPT (0.53) MEN1KMT2APTGS1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases AXXIMA PHARMACEUTICALS AG (DE) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases PRNP, PSEN1, PPP5C PIK3R1 3081/4885PIK3CA 2921/4885MEN1 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.